India Glycols has re-designated Ms. Pragya Bhartia Barwale from Whole Time Director and Key Managerial Person to Non-Executive Non-Independent Director, effective from the closure of business hours on August 12, 2026.

The Board of Directors approved the change during its meeting held on August 12, 2026. The meeting commenced at 3:45 pm and concluded at 4:50 pm.

Ms. Barwale is now liable to retire by rotation. The company confirmed that she is not debarred from holding the office of Director under any SEBI order or other authority.

Key Details

The disclosure was made in pursuance of Regulation 30 and Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

India Glycols Limited india glycols reported a strong start to fiscal year 2027, with consolidated net profit after tax (PAT) rising 32.2% year-on-year to ₹96.8 crore for the quarter ended June 30, 2026. Consolidated revenue from operations grew 19.3% to ₹2,988.4 crore, reflecting continued strength in its core spirits segment and improved operational efficiency across its diversified portfolio.

The Board of Directors approved the unaudited standalone and consolidated financial results in a meeting held on August 12, 2026. The results were reviewed by the Audit Committee on the same date and subjected to a limited review by statutory auditors K.N. Gutgutia & Co.

Financial Highlights

The company’s top-line growth was broad-based, with significant contributions from its potable spirits and bio-based specialities segments. Consolidated EBITDA expanded 12.5% to ₹169.9 crore, indicating improved operating leverage despite higher input costs.

On a standalone basis, revenue rose 19.3% to ₹2,986.9 crore, while net profit increased 44.9% to ₹76.6 crore. Standalone EBITDA grew 14.1% to ₹170.3 crore. The improvement in standalone profitability was partly offset by lower other income compared to the previous year, which had included significant dividend income.

Segment Performance

The potable spirits segment remained the primary revenue driver, contributing ₹2,218.7 crore (74.2% of total revenue), up 22.9% year-on-year. This segment generated an operating profit of ₹75.0 crore, up 3.7% from ₹72.3 crore in Q1FY26, demonstrating stable margin retention despite volume growth.

The bio-based specialities and performance chemicals segment saw revenue rise 20.6% to ₹363.3 crore, with operating profit holding steady at ₹31.4 crore. Ennature Biopharma reported a sharp recovery in profitability, with operating profit jumping to ₹7.3 crore from ₹1.2 crore in the prior year quarter, alongside revenue growth of 64.9% to ₹83.3 crore.

Joint Venture Contribution

A key driver of the consolidated profit surge was the share of net profit from joint ventures, which stood at ₹20.6 crore in Q1FY27, compared to ₹18.6 crore in Q1FY26. This represents approximately 21% of the total consolidated PAT, highlighting the strategic importance of the company’s joint venture partnerships, particularly Clariant IGL Specialty Chemicals Private Limited.

What the Numbers Show

The divergence between standalone and consolidated profit growth warrants attention. While standalone PAT grew 44.9%, consolidated PAT grew 32.2%. This is primarily due to the proportionate impact of the joint venture’s profit contribution, which is included only in the consolidated figures. Furthermore, the standalone EBITDA margin contracted slightly to 5.7% from 6.0% in Q1FY26, whereas the consolidated EBITDA margin improved to 5.7% from 6.0%, suggesting that the mix shift towards higher-margin spirits sales helped cushion input cost pressures at the group level.

Corporate Developments

The company continues to pursue its Composite Scheme of Arrangement, involving the demerger of its Bio Pharma undertaking into Ennature Bio Pharma Limited and its Spirits & Biofuel Undertaking into IGL Spirits Limited. The National Company Law Tribunal (NCLT) sanctioned the scheme on July 17, 2026. The appointed date for the scheme is April 1, 2026. Management confirmed that these structural changes have no bearing on the current quarter’s financial results.

Earnings Call Details

India Glycols will host an earnings conference call on Friday, August 14, 2026, at 4:00 pm IST to discuss the Q1FY27 results. Key participants include CEO Rupark Sarswat, CFO Anand Singhal, and Executive Director Manoj Kumar Rai. Investors can dial in using the universal number +91 22 6280 1527 or +91 22 7115 8322.